RG-239
RG-239 is an orally active TGR5 agonist with an EC50 of 120 nM, significantly outperforming Betulinic acid (HY-10529) (EC50 = 1.04 μM) . RG-239 demonstrates higher selectivity for TGR5 compared to the FXRα. RG-239 increases mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. RG-239 inhibits LPS (HY-D1056) -induced iNOS expression and nitrite production in Raw264.7 and microglia cells. RG-239 can be used for the study of type 2 diabetes[1][2][3][4][5].
Product Specifications
CAS Number
[1199222-56-4]
UNSPSC
12352211
Target
G protein-coupled Bile Acid Receptor 1
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Smiles
OC([C@]12[C@@]([C@@H](CC2)C(C)=C)([H])[C@]3([H])[C@@](CC1)([C@]4([C@]([C@@]5([C@@](C(C)([C@](O)(CC=C)CC5)C)([H])CC4)C)([H])CC3)C)C)=O
Molecular Formula
C33H52O3
Molecular Weight
496.76
References & Citations
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-177050/
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items